

David W Denning

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/299534/publications.pdf>

Version: 2024-02-01

664
papers

73,746
citations

1099

112
h-index

718

252
g-index

693
all docs

693
docs citations

693
times ranked

33750
citing authors

#	ARTICLE	IF	CITATIONS
1	A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL). <i>Thorax</i> , 2022, 77, 821-828.	5.6	15
2	Defective Interferon-Gamma Production Is Common in Chronic Pulmonary Aspergillosis. <i>Journal of Infectious Diseases</i> , 2022, 225, 1822-1831.	4.0	9
3	Prospective Evaluation of Positivity Rates of Aspergillus-Specific IgG and Quality of Life in HIV-Negative Tuberculosis Patients in Lagos, Nigeria. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 790134.	3.9	3
4	Antifungal drug resistance: an update. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, 109-112.	1.1	34
5	Histoplasmosis in Africa: Current perspectives, knowledge gaps, and research priorities. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010111.	3.0	12
6	Burden of serious fungal infections in Honduras. <i>Mycoses</i> , 2022, 65, 429-439.	4.0	1
7	Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. <i>European Respiratory Journal</i> , 2022, 59, 2102950.	6.7	9
8	Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 411.	3.5	2
9	Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda. <i>Mycoses</i> , 2022, 65, 625-634.	4.0	10
10	Estimated Incidence and Prevalence of Serious Fungal Infections in Morocco. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 400.	3.5	1
11	Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 400.	3.5	9
12	Pulmonary and Extrapulmonary Manifestations of Fungal Infections Misdiagnosed as Tuberculosis: The Need for Prompt Diagnosis and Management. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 460.	3.5	20
13	Cryptococcal and <i>Histoplasma</i> Antigen Screening Among People With Human Immunodeficiency Virus in Ghana and Comparative Analysis of <i>Histoplasma</i> Lateral Flow Assay and <i>Histoplasma</i> Enzyme Immunoassay. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	14
14	Chronic Respiratory Diseases Burden and Healthcare Facilities. <i>The Indian Journal of Chest Diseases & Allied Sciences</i> , 2022, 64, 61-62.	0.1	0
15	The global incidence and diagnosis of fungal keratitis. <i>Lancet Infectious Diseases</i> , 2021, 21, e49-e57.	9.1	172
16	The burden of serious fungal infections in Azerbaijan. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110439.	1.8	2
17	The burden of serious fungal infections in Sierra Leone: a national estimate. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110279.	1.8	4
18	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , 2021, 21, 16-18.	9.1	18

#	ARTICLE	IF	CITATIONS
19	Drugâ€“drug interaction database for safe prescribing of systemic antifungal agents. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110106.	1.8	2
20	Fungal infections in transplant recipients: pros and cons of immunosuppressive and antimicrobial treatment. <i>Lancet Microbe</i> , The, 2021, 2, e6-e8.	7.3	3
21	BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. <i>ERJ Open Research</i> , 2021, 7, 00775-2020.	2.6	4
22	Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect <i>Aspergillus</i> -specific antibodies in chronic pulmonary aspergillosis. <i>Respiratory Medicine</i> , 2021, 178, 106290.	2.9	10
23	Performance of LDBio <i>Aspergillus</i> WB and ICT Antibody Detection in Chronic Pulmonary Aspergillosis. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 311.	3.5	6
24	A Rapid Screening Program for Histoplasmosis, Tuberculosis, and Cryptococcosis Reduces Mortality in HIV Patients from Guatemala. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 268.	3.5	22
25	Histoplasmosis in the Republic of Congo dominated by African histoplasmosis, <i>Histoplasma capsulatum</i> var. <i>duboisii</i> . <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009318.	3.0	12
26	Fungal asthma among Ugandan adult asthmatics. <i>Medical Mycology</i> , 2021, 59, 923-933.	0.7	10
27	Evaluation of an <i>Aspergillus</i> IgG/IgM lateral flow assay for serodiagnosis of fungal asthma in Uganda. <i>PLoS ONE</i> , 2021, 16, e0252553.	2.5	8
28	Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detection enzyme immunoassay: A pilot study in Cameroon. <i>Journal of Microbiological Methods</i> , 2021, 185, 106226.	1.6	11
29	Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 767.	9.1	9
30	Serious fungal disease incidence and prevalence in Indonesia. <i>Mycoses</i> , 2021, 64, 1203-1212.	4.0	10
31	Serious fungal diseases in Democratic Republic of Congo â€“ Incidence and prevalence estimates. <i>Mycoses</i> , 2021, 64, 1159-1169.	4.0	7
32	Histoplasmosis in Children; HIV/AIDS Not a Major Driver. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 530.	3.5	11
33	Chronic Pulmonary Aspergillosis Situation among Post Tuberculosis Patients in Vietnam: An Observational Study. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 532.	3.5	14
34	Determining the burden of fungal infections in Zimbabwe. <i>Scientific Reports</i> , 2021, 11, 13240.	3.3	11
35	Characterisation of <i>Aspergillus fumigatus</i> Endocytic Trafficking within Airway Epithelial Cells Using High-Resolution Automated Quantitative Confocal Microscopy. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 454.	3.5	14
36	The challenge of access to refined fungal diagnosis: An investment case for low- and middle-income countries. <i>Journal De Mycologie Medicale</i> , 2021, 31, 101140.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Impact of the COVID-19 pandemic on HIV care in Guatemala. <i>International Journal of Infectious Diseases</i> , 2021, 108, 422-427.	3.3	16
38	Is an azole-resistant <i>Aspergillus</i> hotspot emerging in South-East Asia?. <i>Environmental Microbiology</i> , 2021, 23, 7275-7277.	3.8	5
39	The global burden of chromoblastomycosis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009611.	3.0	40
40	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab441.	0.9	3
41	Updated estimated incidence and prevalence of serious fungal infections in Trinidad and Tobago. <i>IJID Regions</i> , 2021, . .	1.3	2
42	Novel therapeutic options for invasive fungal infections. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 2100265.	2.5	0
43	Estimated Burden Of Serious Fungal Infections In Togo. <i>Mycoses</i> , 2021, 64, 1535-1541.	4.0	2
44	Prevalence of <i>Aspergillus fumigatus</i> skin positivity in adults without an apparent/known atopic disease in Uganda. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110390.	1.8	2
45	One Health aspects & priority roadmap for fungal diseases : A mini-review. <i>Indian Journal of Medical Research</i> , 2021, 153, 311.	1.0	18
46	Standardization of <i>Aspergillus</i> IgG diagnostic cutoff in Nigerians. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110501.	1.8	1
47	Risk factors associated with respiratory infectious disease-related presenteeism: a rapid review. <i>BMC Public Health</i> , 2021, 21, 1955.	2.9	29
48	Estimated Burden of Fungal Infections in Oman. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 5.	3.5	6
49	A global call for talaromycosis to be recognised as a neglected tropical disease. <i>The Lancet Global Health</i> , 2021, 9, e1618-e1622.	6.3	52
50	Evaluation of multiple open-source deep learning models for detecting and grading COVID-19 on chest radiographs. <i>Journal of Medical Imaging</i> , 2021, 8, 064502.	1.5	0
51	Incidence of Histoplasmosis in a Cohort of People with HIV: From Estimations to Reality. <i>Microorganisms</i> , 2021, 9, 2596.	3.6	13
52	Recovery from Copperhead Snake Envenomation: Role of Age, Sex, Bite Location, Severity, and Treatment. <i>Journal of Medical Toxicology</i> , 2020, 16, 17-23.	1.5	3
53	The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz534.	0.9	24
54	Linking calcium signaling and mitochondrial function in fungal drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1254-1256.	7.1	6

#	ARTICLE	IF	CITATIONS
55	Bridging the knowledge gap on mycoses in Africa: Setting up a Pan-African Mycology Working Group. <i>Mycoses</i> , 2020, 63, 244-249.	4.0	18
56	The global distribution of actinomycetoma and eumycetoma. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008397.	3.0	53
57	Human Fungal Infections in Kuwait—Burden and Diagnostic Gaps. <i>Journal of Fungi (Basel)</i> , 2020, 6, 10784314.	3.5	10
58	The one health problem of azole resistance in <i>Aspergillus fumigatus</i> : current insights and future research agenda. <i>Fungal Biology Reviews</i> , 2020, 34, 202-214.	4.7	68
59	The role of antifungals in the management of patients with severe asthma. <i>Clinical and Translational Allergy</i> , 2020, 10, 46.	3.2	22
60	Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. <i>European Respiratory Journal</i> , 2020, 56, 2002554.	6.7	98
61	Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115124.	1.8	14
62	Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV. <i>Aids</i> , 2020, 34, 1625-1632.	2.2	23
63	Optimising the cut-off of the Bordier <i>Aspergillus</i> IgG ELISA for the diagnosis of chronic pulmonary aspergillosis. <i>Journal of Microbiological Methods</i> , 2020, 176, 106021.	1.6	5
64	Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 284-285.	2.2	2
65	Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2. <i>British Dental Journal</i> , 2020, 229, 521-524.	0.6	20
66	Deciphering <i>Aspergillus fumigatus</i> cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3501-3509.	3.0	9
67	Evaluation of the LDBio <i>Aspergillus</i> ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis. <i>PLoS ONE</i> , 2020, 15, e0238855.	2.5	20
68	The global impact of <i>Aspergillus</i> infection on COPD. <i>BMC Pulmonary Medicine</i> , 2020, 20, 241.	2.0	52
69	The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 2233-2237.	3.0	2
70	Risk-Based Estimate of Human Fungal Disease Burden, China. <i>Emerging Infectious Diseases</i> , 2020, 26, 2137-2147.	4.3	31
71	Impact of high baseline <i>Aspergillus</i> -specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis. <i>Medical Mycology</i> , 2020, 58, 1000-1004.	0.7	6
72	Chronic Pulmonary Histoplasmosis—A Scoping Literature Review. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa119.	0.9	28

#	ARTICLE	IF	CITATIONS
73	The antiseptic Miramistin: a review of its comparative in vitro and clinical activity. <i>FEMS Microbiology Reviews</i> , 2020, 44, 399-417.	8.6	16
74	Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture. <i>MBio</i> , 2020, 11, .	4.1	275
75	Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 997-1003.	1.4	16
76	Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and meta-analysis. <i>Mycoses</i> , 2020, 63, 921-927.	4.0	7
77	Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 75.	3.5	28
78	European confederation of medical mycology expert consultation: An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	4.0	8
79	Current burden of serious fungal infections in Republic of Congo. <i>Mycoses</i> , 2020, 63, 543-552.	4.0	7
80	Re-drawing the Maps for Endemic Mycoses. <i>Mycopathologia</i> , 2020, 185, 843-865.	3.1	148
81	Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1125-1132.	5.6	34
82	Integration of fungal diseases into health systems in Latin America. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 890-892.	9.1	4
83	Tackling cryptococcal meningitis in Nigeria, one-step at a time; the impact of training. <i>PLoS ONE</i> , 2020, 15, e0235577.	2.5	5
84	Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy. <i>Clinical Infection in Practice</i> , 2020, 5, 100015.	0.5	10
85	Mycetoma in Uganda: A neglected tropical disease. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008240.	3.0	24
86	Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis: effects on frequency of acute exacerbation and all-cause hospital admission. <i>Thorax</i> , 2020, 75, 513-516.	5.6	12
87	Burden of serious fungal infections in the Netherlands. <i>Mycoses</i> , 2020, 63, 625-631.	4.0	23
88	Skin prick reactivity among asthmatics in East Africa. <i>World Allergy Organization Journal</i> , 2020, 13, 100130.	3.5	9
89	Evaluation of knowledge and awareness of invasive fungal infections amongst resident doctors in Nigeria. <i>Pan African Medical Journal</i> , 2020, 36, 297.	0.8	16
90	Opportunistic fungal infections in persons living with advanced HIV disease in Lagos, Nigeria; a 12-year retrospective study. <i>African Health Sciences</i> , 2020, 20, 1573-81.	0.7	6

#	ARTICLE	IF	CITATIONS
91	Prophylaxis and Treatment of Invasive Aspergillosis: Who and How of Prophylaxis, Treatment, and New Therapies. <i>Current Treatment Options in Infectious Diseases</i> , 2020, 12, 54-70.	1.9	0
92	Title is missing!. , 2020, 15, e0238855.		0
93	Title is missing!. , 2020, 15, e0238855.		0
94	Title is missing!. , 2020, 15, e0238855.		0
95	Title is missing!. , 2020, 15, e0238855.		0
96	Siemens Immulite <i>Aspergillus</i> -specific IgG assay for chronic pulmonary aspergillosis diagnosis. <i>Medical Mycology</i> , 2019, 57, 300-307.	0.7	18
97	Estimated burden of serious human fungal diseases in Turkey. <i>Mycoses</i> , 2019, 62, 22-31.	4.0	13
98	Prospective study of the serum <i>Aspergillus</i> -specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis. <i>BMC Infectious Diseases</i> , 2019, 19, 694.	2.9	15
99	National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1121-1134.	2.5	9
100	Estimated burden of fungal infections in Sweden. <i>Mycoses</i> , 2019, 62, 1043-1048.	4.0	8
101	The Burden of Serious Fungal Infections in Kyrgyzstan. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 66.	3.5	4
102	The Burden of Serious Fungal Infections in Tajikistan. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 68.	3.5	4
103	Mapping histoplasmosis in South East Asia – implications for diagnosis in AIDS. <i>Emerging Microbes and Infections</i> , 2019, 8, 1139-1145.	6.5	35
104	An evaluation of nebulised amphotericin B deoxycholate (Fungizone [®]) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre. <i>Mycoses</i> , 2019, 62, 1049-1055.	4.0	12
105	Estimated Burden of Fungal Infections in Namibia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 75.	3.5	12
106	Getting Histoplasmosis on the Map of International Recommendations for Patients with Advanced HIV Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 80.	3.5	26
107	The Diagnosis of Fungal Neglected Tropical Diseases (Fungal NTDs) and the Role of Investigation and Laboratory Tests: An Expert Consensus Report. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 122.	2.3	38
108	Fungal Diseases in Taiwan – National Insurance Data and Estimation. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 77.	3.5	7

#	ARTICLE	IF	CITATIONS
109	Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. <i>European Respiratory Journal</i> , 2019, 53, 1801184.	6.7	103
110	Evaluation of LDBio <i>Aspergillus</i> ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	36
111	Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1581-1584.	2.9	28
112	Stress-Induced Changes in the Lipid Microenvironment of β -(1,3)-D-Glucan Synthase Cause Clinically Important Echinocandin Resistance in <i>Aspergillus fumigatus</i> . <i>MBio</i> , 2019, 10, .	4.1	48
113	Estimated Burden of Serious Fungal Infections in Ghana. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 38.	3.5	22
114	The case for paracoccidioidomycosis to be accepted as a neglected tropical (fungal) disease. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007195.	3.0	39
115	Burden of fungal asthma in Africa: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0216568.	2.5	43
116	Detection of <i>Pneumocystis jirovecii</i> by quantitative real-time PCR in oral rinses from <i>Pneumocystis pneumonia</i> asymptomatic human immunodeficiency virus patients. <i>Journal De Mycologie Medicale</i> , 2019, 29, 107-111.	1.5	7
117	Pathophysiological aspects of <i>Aspergillus</i> colonization in disease. <i>Medical Mycology</i> , 2019, 57, S219-S227.	0.7	79
118	The validity, reliability and minimal clinically important difference of the patient specific functional scale in snake envenomation. <i>PLoS ONE</i> , 2019, 14, e0213077.	2.5	14
119	The Burden of Fungal Infections in Ethiopia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 109.	3.5	25
120	Diagnostic Aspects of Chronic Pulmonary Aspergillosis: Present and New Directions. <i>Current Fungal Infection Reports</i> , 2019, 13, 292-300.	2.6	14
121	The role of medical mycology societies in combating invasive fungal infections in low- and middle-income countries: A Nigerian model. <i>Mycoses</i> , 2019, 62, 16-21.	4.0	8
122	Inducible Cell Fusion Permits Use of Competitive Fitness Profiling in the Human Pathogenic Fungus <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
123	Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1056-1061.	3.0	11
124	Chronic pulmonary aspergillosis following pulmonary embolism. <i>Medical Mycology Case Reports</i> , 2019, 23, 20-22.	1.3	3
125	Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. <i>Medical Mycology</i> , 2019, 57, 133-150.	0.7	152
126	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e143-e147.	9.1	63

#	ARTICLE	IF	CITATIONS
127	Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis. <i>Mycoses</i> , 2019, 62, 152-156.	4.0	12
128	In vitro and in vivo efficacy of miramistin against drug-resistant fungi. <i>Journal of Medical Microbiology</i> , 2019, 68, 1047-1052.	1.8	11
129	From culturomics to metagenomics: the mycobiome in chronic respiratory diseases. , 2019, , 88-118.		7
130	Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma. <i>Clinical Infectious Diseases</i> , 2018, 67, 156-157.	5.8	8
131	Receiver operating characteristic curve analysis of four <i>Aspergillus</i> -specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 47-51.	1.8	31
132	Corticosteroid treatment is associated with increased filamentous fungal burden in allergic fungal disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 407-414.	2.9	76
133	F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis. <i>Journal of Asthma</i> , 2018, 55, 837-843.	1.7	14
134	A Review of Onychomycosis Due to <i>Aspergillus</i> Species. <i>Mycopathologia</i> , 2018, 183, 485-493.	3.1	63
135	Estimated burden of fungal infections in Italy. <i>Journal of Infection</i> , 2018, 76, 103-106.	3.3	11
136	Acute kidney injury: an unusual complication of posaconazole use. <i>Journal of Chemotherapy</i> , 2018, 30, 380-383.	1.5	5
137	Burden of Serious Fungal Infections in Jordan. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 15.	3.5	18
138	Lung colonization by <i>Aspergillus fumigatus</i> is controlled by ZNF77. <i>Nature Communications</i> , 2018, 9, 3835.	12.8	40
139	An Estimate of the Burden of Fungal Disease in Norway. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 29.	3.5	8
140	Nebulised N-Acetylcysteine for Unresponsive Bronchial Obstruction in Allergic Brochopulmonary Aspergillosis: A Case Series and Review of the Literature. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 117.	3.5	10
141	<i>Histoplasma capsulatum</i> antigen detection tests as an essential diagnostic tool for patients with advanced HIV disease in low and middle income countries: A systematic review of diagnostic accuracy studies. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006802.	3.0	44
142	Diagnosis and Management of <i>Pneumocystis</i> Pneumonia in Resource-poor Settings. <i>Journal of Health Care for the Poor and Underserved</i> , 2018, 29, 107-158.	0.8	14
143	Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. <i>PLoS ONE</i> , 2018, 13, e0193732.	2.5	68
144	Global burden of recurrent vulvovaginal candidiasis: a systematic review. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e339-e347.	9.1	334

#	ARTICLE	IF	CITATIONS
145	Estimated Burden of Serious Fungal Diseases in Serbia. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 76.	3.5	11
146	Estimating the Burden of Serious Fungal Infections in Uruguay. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 37.	3.5	10
147	Estimated Burden of Serious Fungal Infections in Malawi. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 61.	3.5	14
148	Anti-Aspergillus Activities of the Respiratory Epithelium in Health and Disease. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 51.	3.5	51
149	The Burden of Fungal Diseases in Romania. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 31.	3.5	17
150	Burden of Severe Fungal Infections in Burkina Faso. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 35.	3.5	10
151	Estimation of the Burden of Serious Human Fungal Infections in Malaysia. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 14.	3.5	14
152	Burden of Fungal Infections in Colombia. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 41.	3.5	29
153	The Burden of Serious Fungal Infections in Cameroon. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 44.	3.5	28
154	Estimated Burden of Serious Fungal Infections in Mozambique. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 75.	3.5	23
155	Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. <i>Emerging Infectious Diseases</i> , 2018, 24, .	4.3	89
156	Burden of Serious Fungal Infections in Argentina. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 51.	3.5	18
157	An Estimate of Severe and Chronic Fungal Diseases in the Republic of Kazakhstan. <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 34.	3.5	7
158	Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 258-264.	2.5	15
159	Mutations in EEA1 are associated with allergic bronchopulmonary aspergillosis and affect phagocytosis of <i>Aspergillus fumigatus</i> by human macrophages. <i>PLoS ONE</i> , 2018, 13, e0185706.	2.5	17
160	Prior subclinical histoplasmosis revealed in Nigeria using histoplasmin skin testing. <i>PLoS ONE</i> , 2018, 13, e0196224.	2.5	17
161	Diagnosis of chronic pulmonary aspergillosis (CPA) complicating pulmonary tuberculosis by chest X-ray. , 2018, , .		1
162	Histoplasmosis in Africa: An emerging or a neglected disease?. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006046.	3.0	125

#	ARTICLE	IF	CITATIONS
163	Burden of fungal infections in Iran. <i>Journal of Infection in Developing Countries</i> , 2018, 12, 910-918.	1.2	19
164	Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century. <i>Medical Mycology</i> , 2017, 55, myw136.	0.7	27
165	Serious fungal infections in Pakistan. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 949-956.	2.9	43
166	Serious fungal infections in Chile. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 983-986.	2.9	15
167	Burden of fungal infections in Algeria. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 999-1004.	2.9	24
168	Serious fungal infections in the Philippines. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 937-941.	2.9	19
169	Serious fungal infections in Thailand. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 931-935.	2.9	27
170	Serious fungal infections in Peru. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 943-948.	2.9	12
171	Serious fungal infections in Egypt. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 971-974.	2.9	36
172	Burden of serious fungal infections in Guatemala. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 965-969.	2.9	26
173	Serious fungal infections in Korea. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 957-963.	2.9	14
174	Burden of serious fungal infections in Bangladesh. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 993-997.	2.9	23
175	Serious fungal infections in Canada. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 987-992.	2.9	35
176	Predictors of mortality in chronic pulmonary aspergillosis. <i>European Respiratory Journal</i> , 2017, 49, 1601062.	6.7	120
177	Serious fungal infections in Ecuador. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 975-981.	2.9	10
178	Serious fungal diseases in the Republic of Uzbekistan. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 925-929.	2.9	11
179	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 873-881.	9.1	1,559
180	World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine. <i>Clinical Infectious Diseases</i> , 2017, 64, 986-987.	5.8	11

#	ARTICLE	IF	CITATIONS
181	Successful long-term terbinafine therapy in an asthmatic patient with <i>Aspergillus</i> sensitization and bronchiectasis. <i>Medical Mycology Case Reports</i> , 2017, 16, 31-33.	1.3	6
182	The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. <i>Annals of Emergency Medicine</i> , 2017, 70, 233-244.e3.	0.6	59
183	Identifying rare diseases using electronic medical records: the example of allergic bronchopulmonary aspergillosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 785-791.	1.9	12
184	Genetic susceptibility to severe asthma with fungal sensitization. <i>International Journal of Immunogenetics</i> , 2017, 44, 93-106.	1.8	35
185	Tuberculosis/cryptococcosis co-infection in China between 1965 and 2016. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	6.5	39
186	Emergence of Echinocandin Resistance Due to a Point Mutation in the <i>fkp1</i> Gene of <i>Aspergillus fumigatus</i> in a Patient with Chronic Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	55
187	Sarcoidosis and aspergillosis: a tough combination. <i>European Respiratory Journal</i> , 2017, 49, 1700574.	6.7	4
188	<i>Aspergillus</i> nodules in chronic granulomatous disease attributable to <i>Aspergillus ochraceus</i> . <i>Medical Mycology Case Reports</i> , 2017, 17, 31-33.	1.3	8
189	Improvement of fungal disease identification and management: combined health systems and public health approaches. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e412-e419.	9.1	51
190	Pulmonary and sinus fungal diseases in non-immunocompromised patients. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e357-e366.	9.1	84
191	Recovery from serious fungal infections should be realisable for everyone. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1111-1113.	9.1	26
192	The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach. <i>Current Fungal Infection Reports</i> , 2017, 11, 242-251.	2.6	55
193	Comparative performance of <i>Aspergillus</i> galactomannan ELISA and PCR in sputum from patients with ABPA and CPA. <i>Journal of Microbiological Methods</i> , 2017, 140, 32-39.	1.6	23
194	Calling upon all public health mycologists. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 923-924.	2.9	45
195	Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection?. <i>Mycopathologia</i> , 2017, 182, 1125-1129.	3.1	2
196	Opportunistic and Systemic Fungi. , 2017, , 1681-1709.e3.		5
197	Estimating the burden of invasive and serious fungal disease in the United Kingdom. <i>Journal of Infection</i> , 2017, 74, 60-71.	3.3	72
198	Chronic fibrosing pulmonary aspergillosis: a cause of "destroyed lung" syndrome. <i>Infectious Diseases</i> , 2017, 49, 296-301.	2.8	15

#	ARTICLE	IF	CITATIONS
199	Aspergillosis and the role of mucins in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017, 52, 548-555.	2.0	28
200	Future Research Priorities in Fungal Resistance. <i>Journal of Infectious Diseases</i> , 2017, 216, S484-S492.	4.0	26
201	Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis. <i>BMC Pulmonary Medicine</i> , 2017, 17, 149.	2.0	28
202	<i>Aspergillus niger</i> infection in an immunosuppressed patient confined solely to the brain. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218658.	0.5	7
203	Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities. <i>Emerging Infectious Diseases</i> , 2017, 23, 177-183.	4.3	65
204	Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2017, 3, 67.	3.5	21
205	HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for "Prevention Is Better Than Cure". <i>Journal of Fungi (Basel, Switzerland)</i> , 2017, 3, 67.	3.5	33
206	Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. <i>Journal of Fungi (Basel, Switzerland)</i> , 2017, 3, 67.	3.5	1,642
207	Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1056-1061.	1.2	61
208	Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis. <i>Journal of Medical Microbiology</i> , 2017, 66, 898-904.	1.8	27
209	An investigation of antifungal stewardship programmes in England. <i>Journal of Medical Microbiology</i> , 2017, 66, 1581-1589.	1.8	31
210	Cryptococcal meningitis: A neglected NTD?. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005575.	3.0	47
211	Endogenous <i>Candida</i> endophthalmitis and osteomyelitis associated with CARD9 deficiency. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015214117.	0.5	24
212	The burden of serious human fungal infections in Brazil. <i>Mycoses</i> , 2016, 59, 145-150.	4.0	98
213	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, e1-e60.	5.8	1,861
214	Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis. <i>Journal of Infection</i> , 2016, 73, 485-495.	3.3	29
215	Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2016, 371, 20150468.	4.0	88
216	Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA). <i>Respiratory Medicine</i> , 2016, 114, 117-122.	2.9	15

#	ARTICLE	IF	CITATIONS
217	Global access to antifungal therapy and its variable cost. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3599-3606.	3.0	122
218	Aspergillus arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. <i>Medical Mycology</i> , 2016, 55, myw077.	0.7	25
219	Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study. <i>Allergy, Asthma and Clinical Immunology</i> , 2016, 12, 47.	2.0	37
220	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, 433-442.	5.8	295
221	An estimation of burden of serious fungal infections in France. <i>Journal De Mycologie Medicale</i> , 2016, 26, 385-390.	1.5	71
222	Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis. <i>BMC Pulmonary Medicine</i> , 2016, 16, 123.	2.0	61
223	Microbial yield from physiotherapy assisted sputum production in respiratory outpatients. <i>BMC Pulmonary Medicine</i> , 2016, 16, 23.	2.0	15
224	Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw055.	0.9	20
225	Electrophilic, Activation-Free Fluorogenic Reagent for Labeling Bioactive Amines. <i>Bioconjugate Chemistry</i> , 2016, 27, 1430-1434.	3.6	22
226	Comment on: Antifungal therapy: drug-drug interactions at your fingertips. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2062.1-2062.	3.0	7
227	Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). <i>Journal of Infection</i> , 2016, 72, 240-249.	3.3	110
228	Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. <i>European Respiratory Journal</i> , 2016, 47, 45-68.	6.7	654
229	Burden of serious fungal infections in the Dominican Republic. <i>Journal of Infection and Public Health</i> , 2016, 9, 7-12.	4.1	19
230	Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi. <i>PLoS ONE</i> , 2016, 11, e0158724.	2.5	38
231	Estimated burden of fungal infections in Kenya. <i>Journal of Infection in Developing Countries</i> , 2016, 10, 777-784.	1.2	26
232	<i>A.fumigatus</i> and the bronchial epithelium - A permissive relationship?. , 2016, , .		0
233	Response to pneumococcal polysaccharide vaccination in patients with chronic and allergic aspergillosis. <i>Vaccine</i> , 2015, 33, 7271-7275.	3.8	16
234	The burden of fungal disease in Denmark. <i>Mycoses</i> , 2015, 58, 15-21.	4.0	19

#	ARTICLE	IF	CITATIONS
235	Burden of fungal infections in Senegal. <i>Mycoses</i> , 2015, 58, 63-69.	4.0	30
236	Burden of fungal infections in Qatar. <i>Mycoses</i> , 2015, 58, 51-57.	4.0	34
237	Burden of serious fungal infections in Belgium. <i>Mycoses</i> , 2015, 58, 1-5.	4.0	21
238	Burden of serious fungal infections in Tanzania. <i>Mycoses</i> , 2015, 58, 70-79.	4.0	33
239	Estimated burden of fungal infections in Germany. <i>Mycoses</i> , 2015, 58, 22-28.	4.0	42
240	Burden of serious fungal infections in Nepal. <i>Mycoses</i> , 2015, 58, 45-50.	4.0	29
241	Burden of serious fungal infections in Trinidad and Tobago. <i>Mycoses</i> , 2015, 58, 80-84.	4.0	15
242	Burden of serious fungal infections in Mexico. <i>Mycoses</i> , 2015, 58, 34-44.	4.0	34
243	Burden of serious fungal infections in Ukraine. <i>Mycoses</i> , 2015, 58, 94-100.	4.0	15
244	Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens. <i>PLoS ONE</i> , 2015, 10, e0143165.	2.5	20
245	Antibody testing in aspergillosis—quo vadis?. <i>Medical Mycology</i> , 2015, 53, 417-439.	0.7	81
246	Burden of serious fungal infections in the Czech Republic. <i>Mycoses</i> , 2015, 58, 6-14.	4.0	17
247	Burden of serious fungal diseases in Hungary. <i>Mycoses</i> , 2015, 58, 29-33.	4.0	14
248	Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA. <i>Respiratory Medicine</i> , 2015, 109, 1509-1515.	2.9	25
249	Burden of fungal disease in Ireland. <i>Journal of Medical Microbiology</i> , 2015, 64, 423-426.	1.8	27
250	Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an in vitro pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 633-633.	3.0	1
251	Elevated Levels of the Neutrophil Chemoattractant Pro-Platelet Basic Protein in Macrophages From Individuals With Chronic and Allergic Aspergillosis. <i>Journal of Infectious Diseases</i> , 2015, 211, 651-660.	4.0	17
252	Republished: The clinical spectrum of pulmonary aspergillosis. <i>Postgraduate Medical Journal</i> , 2015, 91, 403-410.	1.8	40

#	ARTICLE	IF	CITATIONS
253	Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). <i>Journal of Asthma</i> , 2015, 52, 289-295.	1.7	45
254	How to bolster the antifungal pipeline. <i>Science</i> , 2015, 347, 1414-1416.	12.6	416
255	British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 461-474.	9.1	155
256	Prospective Multicenter International Surveillance of Azole Resistance in <i>Aspergillus fumigatus</i> . <i>Emerging Infectious Diseases</i> , 2015, 21, 1041-1044.	4.3	302
257	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015, 21-22, 30-40.	14.4	262
258	The ambitious '95-95 by 2025' roadmap for the diagnosis and management of fungal diseases. <i>Thorax</i> , 2015, 70, 613-614.	5.6	48
259	Burden of serious fungal infections in Spain. <i>Clinical Microbiology and Infection</i> , 2015, 21, 183-189.	6.0	54
260	The clinical spectrum of pulmonary aspergillosis. <i>Thorax</i> , 2015, 70, 270-277.	5.6	611
261	Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1056-1062.	3.9	65
262	Lung microbiome is associated with asthma severity in fungal associated asthma. , 2015, , .		4
263	Estimated Burden of Serious Fungal Infections in Jamaica. <i>West Indian Medical Journal</i> , 2015, 64, 245-9.	0.4	9
264	IL-17A in severe asthma, severe asthma with fungal sensitisation and ABPA. , 2015, , .		0
265	Estimating the Burden of Fungal Diseases in Israel. <i>Israel Medical Association Journal</i> , 2015, 17, 374-9.	0.1	7
266	Estimation of the Burden of Chronic and Allergic Pulmonary Aspergillosis in India. <i>PLoS ONE</i> , 2014, 9, e114745.	2.5	95
267	Multi-Country Estimate of Different Manifestations of Aspergillosis in Cystic Fibrosis. <i>PLoS ONE</i> , 2014, 9, e98502.	2.5	90
268	Frequency of <i>Pneumocystis jirovecii</i> in sputum from HIV and TB patients in Namibia. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 349-357.	1.2	18
269	Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT. <i>Clinical Microbiology and Infection</i> , 2014, 20, O960-O968.	6.0	32
270	A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. <i>Clinical Microbiology and Infection</i> , 2014, 20, O480-O488.	6.0	30

#	ARTICLE	IF	CITATIONS
271	Occurrence of azole-resistant species of <i>Aspergillus</i> in the UK environment. <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 276-279.	2.2	51
272	Clinical implications of interferon- γ genetic and epigenetic variants. <i>Immunology</i> , 2014, 143, 499-511.	4.4	38
273	Environmental fungicides and triazole resistance in <i>Aspergillus</i> . <i>Pest Management Science</i> , 2014, 70, 173-178.	3.4	73
274	Editorial Commentary: Prophylactic Echinocandin: Is There a Subgroup of Intensive Care Unit Patients Who Benefit?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1227-1229.	5.8	7
275	Long-Term Stability at $\sim 20^{\circ}\text{C}$ of <i>Aspergillus</i> Galactomannan in Serum and Bronchoalveolar Lavage Specimens. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2108-2111.	3.9	15
276	What is the importance of classifying <i>Aspergillus</i> disease in cystic fibrosis patients?. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 389-392.	2.5	21
277	Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1136-1149.	9.1	91
278	Reply to "Insufficient Demonstration of Long-Term Stability of <i>Aspergillus</i> Galactomannan". <i>Journal of Clinical Microbiology</i> , 2014, 52, 4119-4119.	3.9	3
279	Posaconazole responsive cerebral aspergillosis in an immunocompetent adult. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1825-1827.	1.5	8
280	Antifungal resistance: more research needed. <i>Lancet</i> , The, 2014, 384, 1427.	13.7	20
281	Fungal allergy in asthma—state of the art and research needs. <i>Clinical and Translational Allergy</i> , 2014, 4, 14.	3.2	264
282	Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of <i>Aspergillus</i> quantitative PCR. <i>Mycoses</i> , 2014, 57, 69-78.	4.0	66
283	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. <i>Clinical and Experimental Allergy</i> , 2013, 43, 850-873.	2.9	666
284	High-level expression of <i>cyp51B</i> in azole-resistant clinical <i>Aspergillus fumigatus</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 512-514.	3.0	73
285	Long-term Antifungal Treatment Improves Health Status in Patients With Chronic Pulmonary Aspergillosis: A Longitudinal Analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, 828-835.	5.8	68
286	Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centre's experience. <i>Journal of Cardiothoracic Surgery</i> , 2013, 8, 180.	1.1	87
287	IgE-Mediated Immune Responses and Airway Detection of <i>Aspergillus</i> and <i>Candida</i> in Adult Cystic Fibrosis. <i>Chest</i> , 2013, 143, 1351-1357.	0.8	71
288	Acute <i>Aspergillus</i> pneumonia associated with mouldy tree bark-chippings, complicated by anti-glomerular basement membrane disease causing permanent renal failure. <i>Medical Mycology Case Reports</i> , 2013, 2, 125-127.	1.3	10

#	ARTICLE	IF	CITATIONS
289	Development and Evaluation of a Calibrator Material for Nucleic Acid-Based Assays for Diagnosing Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2403-2405.	3.9	22
290	Novel immunologic classification of aspergillosis in adult cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 560-566.e10.	2.9	180
291	Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. <i>British Journal of Dermatology</i> , 2013, 168, 179-185.	1.5	47
292	Major variations in <i>Aspergillus fumigatus</i> arising within aspergillomas in chronic pulmonary aspergillosis. <i>Mycoses</i> , 2013, 56, 434-441.	4.0	43
293	Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. <i>European Respiratory Journal</i> , 2013, 41, 621-626.	6.7	147
294	The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in <i>Aspergillus fumigatus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1486-1496.	3.0	243
295	Frequency, diagnosis and management of fungal respiratory infections. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 259-265.	2.6	37
296	Editorial Commentary: Voriconazole Resistance in <i>Aspergillus fumigatus</i> : Should We Be Concerned?. <i>Clinical Infectious Diseases</i> , 2013, 57, 521-523.	5.8	43
297	Performance of two <i>Aspergillus</i> IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. <i>Clinical Microbiology and Infection</i> , 2013, 19, E197-E204.	6.0	78
298	Intravenous antibiotics reduce the presence of <i>Aspergillus</i> in adult cystic fibrosis sputum. <i>Thorax</i> , 2013, 68, 652-657.	5.6	62
299	Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. <i>Medical Mycology</i> , 2013, 51, 361-370.	0.7	384
300	Validity and Reliability of the St. George's Respiratory Questionnaire in Assessing Health Status in Patients With Chronic Pulmonary Aspergillosis. <i>Chest</i> , 2013, 144, 623-631.	0.8	42
301	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 269-289.	3.0	428
302	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1304-1304.	3.0	5
303	Voriconazole and Posaconazole Improve Asthma Severity in Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitization. <i>Journal of Asthma</i> , 2012, 49, 423-433.	1.7	116
304	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy--author's response. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 3017-3017.	3.0	3
305	Cavitary Pulmonary Lesion In Allergic Bronchopulmonary Aspergillosis Successfully Treated With Posaconazole. , 2012, , .		0
306	Hidden Killers: Human Fungal Infections. <i>Science Translational Medicine</i> , 2012, 4, 165rv13.	12.4	3,368

#	ARTICLE	IF	CITATIONS
307	Allergic bronchopulmonary mycosis due to <i>Alternaria</i> : Case report and review. <i>Medical Mycology Case Reports</i> , 2012, 1, 20-23.	1.3	17
308	<i>Aspergillus</i> bronchitis without significant immunocompromise. <i>Annals of the New York Academy of Sciences</i> , 2012, 1272, 73-85.	3.8	69
309	Multifocal pulmonary aspergillomas: case series and review. <i>Annals of the New York Academy of Sciences</i> , 2012, 1272, 58-67.	3.8	12
310	Fungi and allergic lower respiratory tract diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 280-291.	2.9	398
311	Sequencing of mitochondrial genomes of nine <i>Aspergillus</i> and <i>Penicillium</i> species identifies mobile introns and accessory genes as main sources of genome size variability. <i>BMC Genomics</i> , 2012, 13, 698.	2.8	131
312	Tackling Human Fungal Infections. <i>Science</i> , 2012, 336, 647-647.	12.6	531
313	The Performance of Real-Time PCR, Galactomannan, and Fungal Culture in the Diagnosis of Invasive Aspergillosis in Ventilated Patients with Chronic Obstructive Pulmonary Disease (COPD). <i>Mycopathologia</i> , 2012, 174, 163-169.	3.1	29
314	Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. <i>International Journal of Immunogenetics</i> , 2012, 39, 224-232.	1.8	32
315	Identification of novel genes conferring altered azole susceptibility in <i>Aspergillus fumigatus</i> . <i>FEMS Microbiology Letters</i> , 2012, 332, 10-19.	1.8	37
316	Azole resistance in <i>Aspergillus</i> : a growing public health menace. <i>Future Microbiology</i> , 2011, 6, 1229-1232.	2.0	89
317	High-frequency Triazole Resistance Found In Nonculturable <i>Aspergillus fumigatus</i> from Lungs of Patients with Chronic Fungal Disease. <i>Clinical Infectious Diseases</i> , 2011, 52, 1123-1129.	5.8	264
318	Pathogenicity of <i>Aspergillus fumigatus</i> mutants assessed in <i>Galleria mellonella</i> matches that in mice. <i>Medical Mycology</i> , 2011, 49, S107-S113.	0.7	137
319	Allergic Bronchopulmonary Aspergillosis and Related Allergic Syndromes. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 682-692.	2.1	72
320	Homogenisation of cystic fibrosis sputum by sonication – An essential step for <i>Aspergillus</i> PCR. <i>Journal of Microbiological Methods</i> , 2011, 85, 75-81.	1.6	42
321	Detection of <i>Aspergillus</i> in lung and other tissue samples using the MycAssay <i>Aspergillus</i> real-time PCR kit. <i>Canadian Journal of Microbiology</i> , 2011, 57, 765-768.	1.7	29
322	Detrimental effect of propylene glycol on natural killer cell and neutrophil function. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 236-238.	2.4	10
323	<i>Aspergillus fumigatus</i> Bronchopneumonia in a Hellenic Shepherd Dog. <i>Journal of the American Animal Hospital Association</i> , 2011, 47, e13-e18.	1.1	18
324	Invasive Aspergillosis in a patient with Asthma post H1N1 Pneumonia D Nayar ¹ , Cook P ¹ , Lim L ¹ , Allison D ¹ , Denning D ² County Durham and Darlington Foundation Trust ¹ National Aspergillosis Centre, University Hospital of South Manchester ² . <i>Journal of Infection</i> , 2011, 63, e103-e104.	3.3	2

#	ARTICLE	IF	CITATIONS
325	Azole Antifungal Resistance Today: Focus on <i>Aspergillus</i> . <i>Current Infectious Disease Reports</i> , 2011, 13, 485-491.	3.0	42
326	Itraconazole associated quadriparesis and edema: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 140.	0.8	8
327	Interrogation of Related Clinical Pan-Azole-Resistant <i>Aspergillus fumigatus</i> Strains: G138C, Y431C, and G434C Single Nucleotide Polymorphisms in <i>cyp51A</i> , Upregulation of <i>cyp51A</i> , and Integration and Activation of Transposon <i>Atf1</i> in the <i>cyp51A</i> Promoter. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5113-5121.	3.2	87
328	Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. <i>European Respiratory Journal</i> , 2011, 37, 865-872.	6.7	355
329	Cryptic Species and Azole Resistance in the <i>Aspergillus niger</i> Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4802-4809.	3.2	112
330	Peripheral neuropathy in patients on long-term triazole antifungal therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2136-2139.	3.0	59
331	A public resource for metabolic pathway mapping of <i>Aspergillus fumigatus</i> Af293. <i>Medical Mycology</i> , 2011, 49, S114-S119.	0.7	8
332	Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. <i>Thorax</i> , 2011, 66, 638-640.	5.6	48
333	Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. <i>Bulletin of the World Health Organization</i> , 2011, 89, 864-872.	3.3	318
334	TOO MANY MOULDY JOINTS “ MARIJUANA AND CHRONIC PULMONARY ASPERGILLOSIS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011005.	1.3	54
335	Multicenter, Prospective Clinical Evaluation of Respiratory Samples from Subjects at Risk for <i>Pneumocystis jirovecii</i> Infection by Use of a Commercial Real-Time PCR Assay. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1872-1878.	3.9	84
336	Mixed mould species in laboratory cultures of respiratory specimens: how should they be reported, and what are the indications for susceptibility testing?: Table 1. <i>Journal of Clinical Pathology</i> , 2011, 64, 543-545.	2.0	7
337	<i>Candida tropicalis</i> in human disease. <i>Critical Reviews in Microbiology</i> , 2010, 36, 282-298.	6.1	96
338	Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 1387-1394.	2.9	40
339	A study on <i>Aspergillus</i> species in houses of asthmatic patients from Sari City, Iran and a brief review of the health effects of exposure to indoor <i>Aspergillus</i> . <i>Environmental Monitoring and Assessment</i> , 2010, 168, 481-487.	2.7	52
340	<i>Aspergillus fumigatus</i> allergen expression is coordinately regulated in response to hydrogen peroxide and cyclic AMP. <i>Clinical and Molecular Allergy</i> , 2010, 8, 15.	1.8	8
341	Azole resistance in allergic bronchopulmonary aspergillosis and <i>Aspergillus</i> bronchitis. <i>Clinical Microbiology and Infection</i> , 2010, 16, 683-688.	6.0	72
342	Molecular Detection and Identification of <i>Zygomycetes</i> Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) Evaluation. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2043-2046.	3.9	83

#	ARTICLE	IF	CITATIONS
343	Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis. <i>Clinical Infectious Diseases</i> , 2010, 51, 1383-1391.	5.8	123
344	Azole antifungal resistance in <i>Aspergillus fumigatus</i> : 2008 and 2009. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2116-2118.	3.0	279
345	A 27-Year-Old Woman With Acute, Severe Asthma Who Developed Respiratory Failure. <i>Chest</i> , 2010, 137, 724-727.	0.8	0
346	Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of <i>Aspergillus fumigatus</i> . <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 146-151.	2.5	35
347	Tremor: a newly described adverse event with long-term itraconazole therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 327-329.	1.9	20
348	<i>Aspergillus</i> DNA contamination in blood collection tubes. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 392-394.	1.8	54
349	Therapy for fungal diseases: opportunities and priorities. <i>Trends in Microbiology</i> , 2010, 18, 195-204.	7.7	268
350	Genetic variability of innate immunity impacts human susceptibility to fungal diseases. <i>International Journal of Infectious Diseases</i> , 2010, 14, e460-e468.	3.3	44
351	Frequency and Evolution of Azole Resistance in <i>Aspergillus fumigatus</i> Associated with Treatment Failure. <i>Emerging Infectious Diseases</i> , 2009, 15, 1068-1076.	4.3	692
352	Using aCGH to study intraspecific genetic variability in two pathogenic molds, <i>Aspergillus fumigatus</i> and <i>Aspergillus flavus</i> . <i>Medical Mycology</i> , 2009, 47, S34-S41.	0.7	15
353	In vitro susceptibility of non- <i>Aspergillus</i> allergenic fungal species to azoles. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 834-836.	3.0	3
354	Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3453-3461.	3.2	77
355	Randomized Controlled Trial of Oral Antifungal Treatment for Severe Asthma with Fungal Sensitization. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 11-18.	5.6	320
356	<i>Aspergillus</i> Genomes and the <i>Aspergillus</i> Cloud. <i>Nucleic Acids Research</i> , 2009, 37, D509-D514.	14.5	17
357	Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring. <i>Clinical Infectious Diseases</i> , 2009, 49, 928-930.	5.8	116
358	Fungal rhinosinusitis. <i>Laryngoscope</i> , 2009, 119, 1809-1818.	2.0	385
359	Aflatoxin and Ochratoxin Production by <i>Aspergillus</i> Species Under Ex Vivo Conditions. <i>Mycopathologia</i> , 2009, 168, 185-191.	3.1	15
360	Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. <i>Clinical and Experimental Allergy</i> , 2009, 39, 1677-1683.	2.9	148

#	ARTICLE	IF	CITATIONS
361	Pattern recognition receptor expression is not impaired in patients with chronic mucocutaneous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. <i>Clinical and Experimental Immunology</i> , 2009, 156, 40-51.	2.6	22
362	The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. <i>Respirology</i> , 2009, 14, 1121-1127.	2.3	62
363	Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2009, 11, 89-93.	1.7	116
364	Standards of care for patients with invasive fungal infections within the United Kingdom: A national audit. <i>Journal of Infection</i> , 2009, 58, 145-153.	3.3	32
365	Excess mortality, length of stay and cost attributable to candidaemia. <i>Journal of Infection</i> , 2009, 59, 360-365.	3.3	68
366	Azole-resistance in <i>Aspergillus</i> : Proposed nomenclature and breakpoints. <i>Drug Resistance Updates</i> , 2009, 12, 141-147.	14.4	222
367	Isolation, identification and susceptibility of <i>Pyrenochaeta romeroi</i> in a case of eumycetoma of the foot in the UK. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 613-614.	2.5	22
368	Invasive pulmonary aspergillosis 10 years post bone marrow transplantation: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 26.	0.8	2
369	Does Itraconazole Improve Quality of Life in Severe Asthma with Fungal Sensitization?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 192-192.	5.6	2
370	EUCAST Technical Note on fluconazole. <i>Clinical Microbiology and Infection</i> , 2008, 14, 193-195.	6.0	83
371	EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. <i>Clinical Microbiology and Infection</i> , 2008, 14, 398-405.	6.0	447
372	EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. <i>Clinical Microbiology and Infection</i> , 2008, 14, 982-984.	6.0	323
373	EUCAST Technical Note on voriconazole. <i>Clinical Microbiology and Infection</i> , 2008, 14, 985-987.	6.0	51
374	Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutaneous candidiasis with or without APECED. <i>Clinical and Experimental Immunology</i> , 2008, 154, 406-414.	2.6	48
375	A case of spotted fever group rickettsiosis imported into the United Kingdom and treated with ciprofloxacin: a case report. <i>Journal of Medical Case Reports</i> , 2008, 2, 98.	0.8	4
376	An aspergilloma caused by <i>Aspergillus flavus</i> . <i>Medical Mycology</i> , 2008, 46, 275-278.	0.7	23
377	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> . 2008. 46. 1813-1821.	5.8	4,375
378	Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2008, 46, 327-360.	5.8	2,432

#	ARTICLE	IF	CITATIONS
379	Voriconazole plasma monitoring. <i>Archives of Disease in Childhood</i> , 2008, 93, 578-581.	1.9	40
380	New and emerging treatments for fungal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, i19-i30.	3.0	157
381	Genomic Islands in the Pathogenic Filamentous Fungus <i>Aspergillus fumigatus</i> . <i>PLoS Genetics</i> , 2008, 4, e1000046.	3.5	473
382	Polymorphisms in Toll-Like Receptor Genes and Susceptibility to Pulmonary Aspergillosis. <i>Journal of Infectious Diseases</i> , 2008, 197, 618-621.	4.0	220
383	Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated <i>Candida tropicalis</i> and <i>Candida krusei</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 161-166.	3.0	55
384	Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4389-4397.	3.6	176
385	Chronic mucocutaneous candidiasis and oesophageal cancer. <i>Medical Mycology</i> , 2008, 46, 85-91.	0.7	50
386	Therapeutic drug monitoring for triazoles. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 580-586.	3.1	128
387	Flucytosine therapeutic monitoring: 15 years experience from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 791-793.	3.0	61
388	Statistical Analyses of Correlation between Fluconazole MICs for <i>Candida</i> spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). <i>Journal of Clinical Microbiology</i> , 2007, 45, 109-111.	3.9	49
389	Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3760-3762.	3.2	21
390	Does One Voriconazole Breakpoint Suit All <i>Candida</i> Species?. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2093-2094.	3.9	6
391	Reply to Verweij et al. <i>Clinical Infectious Diseases</i> , 2007, 44, 1667-1668.	5.8	5
392	Comparison of 2 Studies of Treatment of Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2007, 45, 1106-1108.	5.8	14
393	Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 183-6.	2.3	98
394	Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 285-295.	3.2	35
395	A Cautionary Tale: Lack of Consistency in Allele Sizes between Two Laboratories for a Published Multilocus Microsatellite Typing System. <i>Journal of Clinical Microbiology</i> , 2007, 45, 522-528.	3.9	85
396	What can comparative genomics tell us about species concepts in the genus <i>Aspergillus</i> ?. <i>Studies in Mycology</i> , 2007, 59, 11-17.	7.2	83

#	ARTICLE	IF	CITATIONS
397	Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign. <i>Clinical Infectious Diseases</i> , 2007, 44, 373-379.	5.8	524
398	Genomic analysis of allergen genes in <i>Aspergillus</i> spp.: the relevance of genomics to everyday research. <i>Medical Mycology</i> , 2007, 45, 17-26.	0.7	44
399	Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 93-94.	2.5	47
400	<i>Aspergillus flavus</i> : human pathogen, allergen and mycotoxin producer. <i>Microbiology (United Kingdom)</i> , 2007, 153, 1011-1016.	1.8	716
401	Resistance of <i>Aspergillus fumigatus</i> to several azoles. <i>Journal De Mycologie Medicale</i> , 2007, 17, S11-S15.	1.5	0
402	Multi-azole resistance in <i>Aspergillus fumigatus</i> . <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 450-453.	2.5	199
403	Whole genome comparison of the <i>A. fumigatus</i> family. <i>Medical Mycology</i> , 2006, 44, 3-7.	0.7	42
404	The link between fungi and severe asthma: a summary of the evidence. <i>European Respiratory Journal</i> , 2006, 27, 615-626.	6.7	703
405	Voriconazole Treatment for Subacute Invasive and Chronic Pulmonary Aspergillosis. <i>American Journal of Medicine</i> , 2006, 119, 527.e17-527.e24.	1.5	94
406	Fungal contamination of bedding. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 140-142.	5.7	61
407	Comparison of two fluorescent whiteners, Calcofluor and Blankophor, for the detection of fungal elements in clinical specimens in the diagnostic laboratory. <i>Clinical Microbiology and Infection</i> , 2006, 12, 181-184.	6.0	44
408	Post-operative aspergillosis. <i>Clinical Microbiology and Infection</i> , 2006, 12, 1060-1076.	6.0	144
409	The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. <i>Journal of Infection</i> , 2006, 52, e133-e137.	3.3	78
410	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. <i>Journal of Infection</i> , 2006, 53, 337-349.	3.3	290
411	Antifungal susceptibility testing in <i>Aspergillus</i> spp. according to EUCAST methodology. <i>Medical Mycology</i> , 2006, 44, 319-325.	0.7	57
412	Cytokine profiling of pulmonary aspergillosis. <i>International Journal of Immunogenetics</i> , 2006, 33, 297-302.	1.8	74
413	Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. <i>BMC Genomics</i> , 2006, 7, 251.	2.8	68
414	<i>Aspergillus</i> and aspergillosis – Progress on many fronts. <i>Medical Mycology</i> , 2006, 44, S1-S1.	0.7	11

#	ARTICLE	IF	CITATIONS
415	Relative reactivity of <i>Aspergillus</i> allergens used in serological tests. <i>Medical Mycology</i> , 2006, 44, 23-28.	0.7	18
416	Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England. <i>Journal of Clinical Pathology</i> , 2006, 59, 759-763.	2.0	5
417	In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble) Tj ETQq1 1 0.784314 rgBT /Overlock 3.0 86	3.0	86
418	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. <i>Clinical Infectious Diseases</i> , 2006, 43, 1031-1039.	5.8	3
419	Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 384-410.	3.0	157
420	Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against <i>Candida albicans</i> and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3680-3688.	3.2	41
421	Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 945-949.	1.5	25
422	Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated <i>Aspergillus flavus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1198-1207.	3.0	73
423	Sub-cutaneous phaeohyphomycosis caused by <i>Cladophialophora devriesii</i> in a United Kingdom resident. <i>Medical Mycology</i> , 2006, 44, 553-556.	0.7	7
424	Genome sequencing and analysis of <i>Aspergillus oryzae</i> . <i>Nature</i> , 2005, 438, 1157-1161.	27.8	1,128
425	Genomic sequence of the pathogenic and allergenic filamentous fungus <i>Aspergillus fumigatus</i> . <i>Nature</i> , 2005, 438, 1151-1156.	27.8	1,272
426	Sequencing of <i>Aspergillus nidulans</i> and comparative analysis with <i>A. fumigatus</i> and <i>A. oryzae</i> . <i>Nature</i> , 2005, 438, 1105-1115.	27.8	1,250
427	Evidence for Sexuality in the Opportunistic Fungal Pathogen <i>Aspergillus fumigatus</i> . <i>Current Biology</i> , 2005, 15, 1242-1248.	3.9	283
428	Genomics of <i>Aspergillus fumigatus</i> . <i>Revista Iberoamericana De Micologia</i> , 2005, 22, 223-228.	0.9	41
429	Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 628-633.	2.9	19
430	Book Review M.A. Klich, Identification of Common <i>Aspergillus</i> Species, ASM Press, Washington, DC, 2002, 116 pp., \$39.95.. <i>Mycopathologia</i> , 2005, 159, 89-89.	3.1	0
431	Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. <i>BMC Pulmonary Medicine</i> , 2005, 5, 4.	2.0	199
432	Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome. <i>Clinical Infectious Diseases</i> , 2005, 41, 1448-1452.	5.8	106

#	ARTICLE	IF	CITATIONS
433	Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of <i>Candida tropicalis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 590-593.	3.0	31
434	Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5-Fluorocytosine for Treatment of Invasive Candidiasis. <i>Journal of Infectious Diseases</i> , 2005, 192, 673-680.	4.0	18
435	The invasive and saprophytic syndromes due to <i>Aspergillus</i> spp.. <i>Medical Mycology</i> , 2005, 43, 207-238.	0.7	194
436	Laboratory diagnosis of invasive aspergillosis. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 609-622.	9.1	432
437	Correlation between in vitro growth rate and in vivo virulence in <i>Aspergillus fumigatus</i> . <i>Medical Mycology</i> , 2005, 43, 397-401.	0.7	50
438	Evidence for recombination in <i>Candida glabrata</i> . <i>Fungal Genetics and Biology</i> , 2005, 42, 233-243.	2.1	68
439	What the <i>Aspergillus</i> genomes have told us. <i>Medical Mycology</i> , 2005, 43, 3-5.	0.7	31
440	Aspergillosis in Nonimmunocompromised Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 580-581.	5.6	34
441	Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1563-1571.	5.8	617
442	Stevens et al. (2003; 37[Suppl 3]:S225-64). <i>Clinical Infectious Diseases</i> , 2004, 38, 158-158.	5.8	24
443	Molecular Mechanisms of Primary Resistance to Flucytosine in <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4377-4386.	3.2	139
444	Adverse Reactions to Voriconazole. <i>Clinical Infectious Diseases</i> , 2004, 39, 1241-1244.	5.8	177
445	<i>Mycobacterium chelonae</i> finger infection associated with Raynaud's phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1178-1179.	0.9	4
446	Inactivation of Transcription Factor Gene ACE2 in the Fungal Pathogen <i>Candida glabrata</i> Results in Hypervirulence. <i>Eukaryotic Cell</i> , 2004, 3, 546-552.	3.4	70
447	Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against <i>Aspergillus</i> and <i>Candida</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 743-749.	3.0	41
448	Optimising antifungal therapy for individual patients. <i>Internal Medicine Journal</i> , 2004, 34, 147-149.	0.8	5
449	Invasive aspergillosis: current and future challenges in diagnosis and therapy. <i>Clinical Microbiology and Infection</i> , 2004, 10, 2-4.	6.0	30
450	Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist. <i>European Radiology</i> , 2004, 14, 2030-2037.	4.5	12

#	ARTICLE	IF	CITATIONS
451	Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. <i>Journal of Infection</i> , 2004, 49, 136-140.	3.3	5
452	Comparison of extracellular phospholipase activities in clinical and environmental <i>Aspergillus fumigatus</i> isolates. <i>Medical Mycology</i> , 2004, 42, 81-86.	0.7	33
453	Insight into the genome of <i>Aspergillus fumigatus</i> : analysis of a 922kb region encompassing the nitrate assimilation gene cluster. <i>Fungal Genetics and Biology</i> , 2004, 41, 443-453.	2.1	55
454	Validation of an Assay for Voriconazole in Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 650-657.	2.0	66
455	Pulmonary Aspergillosis in a Patient with Chronic Granulomatous Disease: Confirmation by Polymerase Chain Reaction and Serological Tests, and Successful Treatment with Voriconazole. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003, 22, 681-685.	2.9	14
456	<i>Candida glabrata</i> STE12 is required for wild-type levels of virulence and nitrogen starvation induced filamentation. <i>Molecular Microbiology</i> , 2003, 50, 1309-1318.	2.5	64
457	Antifungal activity of human polymorphonuclear and mononuclear phagocytes against non- <i>fumigatus Aspergillus</i> species. <i>Mycoses</i> , 2003, 46, 77-83.	4.0	24
458	Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). <i>Clinical Microbiology and Infection</i> , 2003, 9, 467-474.	6.0	135
459	Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. <i>Clinical Microbiology and Infection</i> , 2003, 9, i-viii.	6.0	122
460	Echinocandin antifungal drugs. <i>Lancet, The</i> , 2003, 362, 1142-1151.	13.7	970
461	British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. <i>Lancet Infectious Diseases, The</i> , 2003, 3, 230-240.	9.1	185
462	Standards of care for invasive fungal infections – Authors' reply. <i>Lancet Infectious Diseases, The</i> , 2003, 3, 402-403.	9.1	0
463	Advances against Aspergillosis. <i>Clinical Infectious Diseases</i> , 2003, 37, S155-S156.	5.8	20
464	Multilocus Sequence Typing of <i>Candida glabrata</i> Reveals Geographically Enriched Clades. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5709-5717.	3.9	172
465	Interlaboratory Evaluation of Hemacytometer Method of Inoculum Preparation for Testing Antifungal Susceptibilities of Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5236-5237.	3.9	69
466	Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. <i>Laboratory Animals</i> , 2003, 37, 126-131.	1.0	64
467	Activity of micafungin (FK463) against an itraconazole-resistant strain of <i>Aspergillus fumigatus</i> and a strain of <i>Aspergillus terreus</i> demonstrating in vivo resistance to amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 913-919.	3.0	68
468	Cutaneous childhood sarcoidosis—a rare disease refractory to treatment. <i>British Journal of Rheumatology</i> , 2003, 42, 1570-1571.	2.3	3

#	ARTICLE	IF	CITATIONS
469	Interactions of human phagocytes with moulds <i>Fusarium</i> spp. and <i>Verticillium nigrescens</i> possessing different pathogenicity. <i>Medical Mycology</i> , 2003, 41, 503-509.	0.7	12
470	Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis – State of the Art: Cystic Fibrosis Foundation Consensus Conference. <i>Clinical Infectious Diseases</i> , 2003, 37, S225-S264.	5.8	658
471	Comparison of three methods for in vitro susceptibility testing of <i>Candida</i> species with flucytosine. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 297-304.	3.0	9
472	In vitro susceptibilities of zygomycetes to conventional and new antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 45-52.	3.0	299
473	Chronic Cavitory and Fibrosing Pulmonary and Pleural Aspergillosis: Case Series, Proposed Nomenclature Change, and Review. <i>Clinical Infectious Diseases</i> , 2003, 37, S265-S280.	5.8	456
474	Combination and Sequential Antifungal Therapy for Invasive Aspergillosis: Review of Published In Vitro and In Vivo Interactions and 6281 Clinical Cases from 1966 to 2001. <i>Clinical Infectious Diseases</i> , 2003, 37, S188-S224.	5.8	169
475	<i>Aspergillus</i> . , 2003, , .		0
476	Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of <i>Aspergillus</i> Species. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2876-2885.	3.9	59
477	Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2002, 34, 563-571.	5.8	807
478	In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against <i>Scenedosporium prolificans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3323-3326.	3.2	41
479	In Vitro Activities of New and Conventional Antifungal Agents against Clinical <i>Scenedosporium</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 62-68.	3.2	230
480	In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against <i>Aspergillus</i> spp.. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 189-194.	3.0	66
481	In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2708-2711.	3.2	78
482	Azole Cross-Resistance in <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 556-557.	3.2	117
483	In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by <i>Candida tropicalis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 1071-1074.	3.0	33
484	Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1953-1959.	3.2	50
485	Echinocandins: a new class of antifungal. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 889-891.	3.0	247
486	Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus. <i>Clinical Infectious Diseases</i> , 2002, 34, 7-14.	5.8	2,255

#	ARTICLE	IF	CITATIONS
487	Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis. <i>New England Journal of Medicine</i> , 2002, 347, 408-415.	27.0	3,048
488	Increased expression of a novel <i>Aspergillus fumigatus</i> ABC transporter gene, <i>atrF</i> , in the presence of itraconazole in an itraconazole resistant clinical isolate. <i>Fungal Genetics and Biology</i> , 2002, 36, 199-206.	2.1	174
489	Sequencing the <i>Aspergillus fumigatus</i> genome. <i>Lancet Infectious Diseases</i> , The, 2002, 2, 251-253.	9.1	81
490	Aspergillosis. <i>Infectious Disease Clinics of North America</i> , 2002, 16, 875-894.	5.1	284
491	Invasive Infection due to <i>Penicillium</i> Species other than <i>P. marneffeii</i> . <i>Journal of Infection</i> , 2002, 45, 184-195.	3.3	101
492	Invasive Infection due to <i>Penicillium</i> Species other than <i>P. marneffeii</i> . <i>Journal of Infection</i> , 2002, 45, 184-195.	3.3	4
493	Increasing Volume and Changing Characteristics of Invasive Pulmonary Aspergillosis on Sequential Thoracic Computed Tomography Scans in Patients With Neutropenia. <i>Journal of Clinical Oncology</i> , 2001, 19, 253-259.	1.6	544
494	Termination of development of D0870. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 47, 720-721.	3.0	10
495	Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 648-653.	1.3	122
496	Fungal infection of the diabetic foot: two distinct syndromes. <i>Diabetic Medicine</i> , 2001, 18, 567-572.	2.3	34
497	Advances in invasive fungal infection and antifungal therapy: Introduction. <i>Clinical Microbiology and Infection</i> , 2001, 7, vi.	6.0	1
498	Antifungal Susceptibility Testing of Fluconazole by Flow Cytometry Correlates with Clinical Outcome. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2458-2462.	3.9	33
499	Mannose-binding Lectin Gene Polymorphisms as a Susceptibility Factor for Chronic Necrotizing Pulmonary Aspergillosis. <i>Journal of Infectious Diseases</i> , 2001, 184, 653-656.	4.0	145
500	A Phase III Study of Recombinant Human Interferon Gamma to Prevent Opportunistic Infections in Advanced HIV Disease. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 789-797.	1.1	57
501	In Vitro Activities of Terbinafine against <i>Aspergillus</i> Species in Comparison with Those of Itraconazole and Amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1882-1885.	3.2	56
502	Susceptibility Testing of <i>Aspergillus flavus</i> : Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B In Vitro and Outcome In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1456-1462.	3.2	57
503	Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses. <i>Clinical Infectious Diseases</i> , 2001, 33, 95-106.	5.8	68
504	Treatment of <i>Absidia corymbifera</i> infection in mice with amphotericin B and itraconazole. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 583-586.	3.0	21

#	ARTICLE	IF	CITATIONS
505	Antifungal Drug Resistance in <i>Aspergillus</i> . <i>Journal of Infection</i> , 2000, 41, 203-220.	3.3	147
506	<i>Candida glabrata</i> Oesophagitis in a Patient Without HIV Infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000, 19, 561-562.	2.9	7
507	In Vivo Activity of Amphotericin B Lipid Complex in Immunocompromised Mice against Fluconazole-Resistant or Fluconazole-Susceptible <i>Candida tropicalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2664-2671.	3.2	21
508	Invasive aspergillosis in a patient with MELAS syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 765-767.	1.9	11
509	Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of <i>Aspergillus</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 85-93.	3.0	96
510	Practice Guidelines for Diseases Caused by <i>Aspergillus</i> . <i>Clinical Infectious Diseases</i> , 2000, 30, 696-709.	5.8	757
511	In Vitro Activity of the New Triazole BMS-207147 against <i>Aspergillus</i> Species in Comparison with Itraconazole and Amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 441-443.	3.2	69
512	Invasive Aspergillosis as an Opportunistic Infection in Nonallografted Patients with Multiple Myeloma: A European Organization for Research and Treatment of Cancer. <i>Clinical Infectious Diseases</i> , 2000, 30, 41-46.	5.8	58
513	Early diagnosis of invasive aspergillosis. <i>Lancet, The</i> , 2000, 355, 2076.	13.7	0
514	Molecular genetics in <i>Aspergillus fumigatus</i> . <i>Current Opinion in Microbiology</i> , 2000, 3, 468-474.	5.1	78
515	Early diagnosis of invasive aspergillosis. <i>Lancet, The</i> , 2000, 355, 423-424.	13.7	64
516	SUCCESSFUL TREATMENT OF ASPERGILLUS BRAIN ABSCESS IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Pediatric Hematology and Oncology</i> , 2000, 17, 497-504.	0.8	22
517	Dose Range Evaluation of Liposomal Nystatin and Comparisons with Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected with an Isolate of <i>Aspergillus fumigatus</i> with Reduced Susceptibility to Amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2592-2599.	3.2	52
518	Comparison of In Vitro Activity of Liposomal Nystatin against <i>Aspergillus</i> Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1264-1266.	3.2	61
519	Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 577-578.	3.0	12
520	Assessment of Therapeutic Response of Oropharyngeal and Esophageal Candidiasis in AIDS with Use of a New Clinical Scoring System: Studies with D0870. <i>Clinical Infectious Diseases</i> , 1999, 28, 587-596.	5.8	5
521	Endemic mycoses: a treatment update. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 43, 321-331.	3.0	107
522	<i>Aspergillus fumigatus</i> catalases: cloning of an <i>Aspergillus nidulans</i> catalase B homologue and evidence for at least three catalases. <i>FEMS Immunology and Medical Microbiology</i> , 1999, 23, 125-133.	2.7	31

#	ARTICLE	IF	CITATIONS
523	Cryptococcal meningitis in the immunocompromised host: intracranial hypertension and other complications. <i>Mycopathologia</i> , 1999, 146, 1-8.	3.1	24
524	Use of the 6-methylsalicylic-acid-synthase gene as a discriminating marker between <i>Aspergillus terreus</i> and <i>Aspergillus flavipes</i> . <i>Folia Microbiologica</i> , 1999, 44, 503-509.	2.3	5
525	Molecular Typing of <i>Aspergillus terreus</i> by Random Amplification of Polymorphic DNA. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 838-841.	2.9	15
526	Invasive yeast infections other than <i>Candida</i> spp. in acute leukaemia. <i>Journal of Hospital Infection</i> , 1999, 41, 181-194.	2.9	103
527	Activity of pradimicin BMS-181184 against <i>Aspergillus</i> spp. <i>International Journal of Antimicrobial Agents</i> , 1999, 12, 267-269.	2.5	8
528	<i>Aspergillus fumigatus</i> catalases: cloning of an <i>Aspergillus nidulans</i> catalase B homologue and evidence for at least three catalases. <i>FEMS Immunology and Medical Microbiology</i> , 1999, 23, 125-133.	2.7	2
529	An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome. <i>Journal of Infection</i> , 1998, 37, 173-180.	3.3	250
530	Variation in morphotype, karyotype and DNA type of fluconazole resistant <i>Candida albicans</i> from an AIDS patient. <i>Journal of Infection</i> , 1998, 36, 57-62.	3.3	12
531	The Treatment of Oropharyngeal Candidiasis in HIV-infected Patients with Oral Amphotericin B Suspension. <i>AIDS Patient Care and STDs</i> , 1998, 12, 625-627.	2.5	7
532	In-vitro activity of voriconazole against <i>Aspergillus</i> spp. and comparison with itraconazole and amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 91-94.	3.0	56
533	Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 1998, 26, 781-803.	5.8	1,522
534	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental <i>Aspergillus fumigatus</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998, 42, 389-392.	3.0	71
535	Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. <i>Aids</i> , 1998, 12, 411-416.	2.2	10
536	Skull base osteitis following fungal sinusitis. <i>Journal of Laryngology and Otology</i> , 1998, 112, 92-97.	0.8	41
537	In Vitro Activity of the Echinocandin Antifungal Agent LY303,366 in Comparison with Itraconazole and Amphotericin B against <i>Aspergillus</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2726-2730.	3.2	79
538	Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant <i>Aspergillus fumigatus</i> in a Murine Model of Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 873-878.	3.2	101
539	Polar lipids of <i>Aspergillus fumigatus</i> , <i>A. niger</i> , <i>A. nidulans</i> , <i>A. flavus</i> and <i>A. terreus</i> . <i>Medical Mycology</i> , 1998, 36, 127-134.	0.7	0
540	Diagnostic and Therapeutic Strategies for Invasive Aspergillosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1997, 18, 203-215.	2.1	21

#	ARTICLE	IF	CITATIONS
541	Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of <i>Aspergillus fumigatus</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 401-414.	3.0	202
542	Echinocandins and pneumocandins--a new antifungal class with a novel mode of action. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 611-614.	3.0	119
543	Amphotericin B resistance testing of <i>Candida</i> spp.: a comparison of methods. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 109-112.	3.0	42
544	Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 779-788.	3.0	20
545	A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. <i>Aids</i> , 1997, 11, 759-763.	2.2	10
546	Prevalence of phthioic acid in <i>Aspergillus</i> species. <i>Medical Mycology</i> , 1997, 35, 143-145.	0.7	8
547	Inhibition and interaction of cytochrome P450 of <i>Candida krusei</i> with azole antifungal drugs. <i>Medical Mycology</i> , 1997, 35, 19-25.	0.7	26
548	<i>Neurospora sitophila</i> Pulmonary Infection in a Patient with AIDS. <i>AIDS Patient Care and STDs</i> , 1997, 11, 223-226.	2.5	3
549	In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against <i>Aspergillus fumigatus</i> and <i>Candida krusei</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 39, 731-736.	3.0	6
550	Partial 16S rDNA analysis of oral <i>Treponema</i> . <i>Reviews in Medical Microbiology</i> , 1997, 8, S25.	0.9	0
551	The challenge of invasive aspergillosis: Increasing numbers in diverse patient groups. <i>International Journal of Infectious Diseases</i> , 1997, 2, 61-63.	3.3	17
552	Itraconazole resistance in <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 1364-1368.	3.2	457
553	Activity of SCH 56592 compared with those of fluconazole and itraconazole against <i>Candida</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 2310-2311.	3.2	58
554	In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against <i>Aspergillus</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 1124-1126.	3.2	101
555	Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 1504-1507.	3.2	111
556	Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997, 16, 424-436.	2.9	152
557	Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant <i>Candida krusei</i> , <i>Candida inconspicua</i> , and <i>Candida norvegensis</i> strains. <i>Journal of Clinical Microbiology</i> , 1997, 35, 1036-1039.	3.9	27
558	High incidence of antifungal drug resistance in <i>Candida tropicalis</i> . <i>International Journal of Antimicrobial Agents</i> , 1996, 7, 241-245.	2.5	14

#	ARTICLE	IF	CITATIONS
559	Aspergillosis: diagnosis and treatment. <i>International Journal of Antimicrobial Agents</i> , 1996, 6, 161-168.	2.5	26
560	Polarized Growth of Fungal Hyphae Is Defined by an Alkaline pH Gradient. <i>Fungal Genetics and Biology</i> , 1996, 20, 289-298.	2.1	46
561	Hyperbaric oxygen therapy in a woman who declined colostomy. <i>Lancet, The</i> , 1996, 348, 197.	13.7	11
562	Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of <i>Candida albicans</i> cytochrome P-450 by using in vitro assays. <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 1382-1386.	3.2	30
563	Reduced accumulation of drug in <i>Candida krusei</i> accounts for itraconazole resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 2443-2446.	3.2	60
564	In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various <i>Candida</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 2229-2231.	3.2	12
565	Rapid genotyping of <i>Escherichia coli</i> O157 isolates by random amplification of polymorphic DNA. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996, 15, 297-302.	2.9	22
566	Acute meningoencephalitis in pregnancy—a problem of differential diagnosis. <i>European Journal of Neurology</i> , 1996, 3, 267-271.	3.3	0
567	<i>Aspergillus</i> wound infection following laparostomy. <i>Journal of Infection</i> , 1996, 33, 119-121.	3.3	20
568	Therapeutic Outcome in Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 1996, 23, 608-615.	5.8	656
569	Evidence of multiple extracellular phospholipase activities of <i>Aspergillus fumigatus</i> . <i>Infection and Immunity</i> , 1996, 64, 751-755.	2.2	81
570	D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. <i>Journal of Clinical Microbiology</i> , 1996, 34, 218-221.	3.9	30
571	Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of <i>Aspergillus fumigatus</i> . <i>Journal of Clinical Microbiology</i> , 1996, 34, 87-93.	3.9	80
572	Uncommon invasive mycoses in AIDS. <i>Aids</i> , 1995, 9, 411-420.	2.2	31
573	DNA typing of epidemiologically-related isolates of <i>Aspergillus fumigatus</i> . <i>Epidemiology and Infection</i> , 1995, 114, 161-168.	2.1	29
574	Aflatoxin and outcome from acute lower respiratory infection in children in The Philippines. <i>Annals of Tropical Paediatrics</i> , 1995, 15, 209-216.	1.0	18
575	, a multi-resistant fungus, from a U.K. AIDS patient. <i>Journal of Infection</i> , 1995, 30, 153-155.	3.3	37
576	Resistance to fluconazole in <i>Candida albicans</i> from AIDS patients correlated with reduced intracellular accumulation of drug. <i>FEMS Microbiology Letters</i> , 1995, 131, 337-341.	1.8	74

#	ARTICLE	IF	CITATIONS
577	Anti-Cryptococcus neoformans antibodies during cryptococcosis in patients with the acquired immunodeficiency syndrome. <i>Serodiagnosis and Immunotherapy in Infectious Disease</i> , 1995, 7, 181-188.	0.2	9
578	In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant <i>Candida</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 868-871.	3.2	44
579	Antifungal drug susceptibility testing: Working Party of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 899-909.	3.0	17
580	Efficacy of oral saperconazole in systemic murine aspergillosis. <i>Medical Mycology</i> , 1995, 33, 311-317.	0.7	36
581	Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 1809-1814.	3.2	51
582	<i>Aspergillus</i> Fungemia: Report of Two Cases and Review. <i>Clinical Infectious Diseases</i> , 1995, 20, 598-605.	5.8	163
583	Commentary: unusual manifestations of aspergillosis.. <i>Thorax</i> , 1995, 50, 812-813.	5.6	66
584	Resistance to fluconazole in <i>Candida albicans</i> from AIDS patients correlated with reduced intracellular accumulation of drug. <i>FEMS Microbiology Letters</i> , 1995, 131, 337-341.	1.8	2
585	Uncommon invasive mycoses in AIDS. <i>Aids</i> , 1995, 9, 411-420.	2.2	0
586	Evolving Etiology of fungal Infection in the 1990s. <i>Infectious Diseases in Clinical Practice</i> , 1994, 3, s56.	0.3	0
587	High prevalence of antifungal resistance in <i>Candida</i> spp. from patients with AIDS. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 34, 659-668.	3.0	144
588	Invasive Aspergillosis in Patients with AIDS. <i>Clinical Infectious Diseases</i> , 1994, 19, S41-S48.	5.8	137
589	Administering amphotericin Bâ€™a practical approach. <i>Journal of Antimicrobial Chemotherapy</i> , 1994, 33, 203-213.	3.0	121
590	Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. <i>Antimicrobial Agents and Chemotherapy</i> , 1994, 38, 1561-1566.	3.2	58
591	<i>Aspergillus</i> Tracheobronchitis. <i>Clinical Infectious Diseases</i> , 1994, 19, 1176-1177.	5.8	8
592	Diagnosis of infections with Shiga-like toxin-producing <i>Escherichia coli</i> by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples. <i>Journal of Medical Microbiology</i> , 1994, 40, 241-245.	1.8	11
593	Oxygen requirements of <i>Aspergillus</i> species. <i>Journal of Medical Microbiology</i> , 1994, 41, 311-315.	1.8	65
594	Successful Treatment of Sinusitis Caused by <i>Cunninghamella bertholletiae</i> . <i>Clinical Infectious Diseases</i> , 1994, 19, 313-316.	5.8	42

#	ARTICLE	IF	CITATIONS
595	Reply to Troke and Hitchcock's letter. <i>Journal of Infection</i> , 1994, 28, 225-227.	3.3	1
596	Treatment of invasive aspergillosis. <i>Journal of Infection</i> , 1994, 28, 25-33.	3.3	62
597	Early management of community-acquired asthma. <i>Respiratory Medicine</i> , 1994, 88, 73-74.	2.9	0
598	NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. <i>American Journal of Medicine</i> , 1994, 97, 135-144.	1.5	474
599	Invasive aspergillosis in immunocompromised patients. <i>Current Opinion in Infectious Diseases</i> , 1994, 7, 456-462.	3.1	48
600	Evolving Etiology of Fungal Infection in the 1990s. <i>Infectious Diseases in Clinical Practice</i> , 1994, 3, S50-S55.	0.3	4
601	Fluconazole-resistant candidosis in an HIV cohort. <i>Aids</i> , 1994, 8, 787-792.	2.2	136
602	Empiric amphotericin B therapy: the need for a reappraisal. <i>Blood Reviews</i> , 1993, 7, 208-214.	5.7	23
603	Fluconazole resistance in <i>Candida</i> in patients with AIDS—A therapeutic approach. <i>Journal of Infection</i> , 1993, 26, 117-125.	3.3	89
604	Temperature-dependent expression of elastase in <i>Aspergillus</i> species. <i>Medical Mycology</i> , 1993, 31, 455-458.	0.7	8
605	Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. <i>Thorax</i> , 1993, 48, 1285-1287.	5.6	24
606	In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against <i>Aspergillus</i> spp.. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 32, 831-836.	3.0	28
607	Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations. <i>Clinical Infectious Diseases</i> , 1992, 14, 165-174.	5.8	206
608	Quantitative preservation of viability of <i>Aspergillus fumigatus</i> . <i>Medical Mycology</i> , 1992, 30, 485-488.	0.7	15
609	Time to finish with "AIDS"? <i>Lancet</i> , The, 1992, 339, 1298.	13.7	2
610	In vitro susceptibility and synergy studies of <i>Aspergillus</i> species to conventional and new agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 1992, 15, 21-34.	1.8	140
611	Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient. <i>Journal of Infection</i> , 1992, 24, 73-79.	3.3	17
612	Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. <i>Journal of Infection</i> , 1992, 24, 212-213.	3.3	6

#	ARTICLE	IF	CITATIONS
613	Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. <i>Infection and Immunity</i> , 1992, 60, 5153-5156.	2.2	45
614	Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. <i>American Journal of Medicine</i> , 1991, 91, 267-272.	1.5	222
615	The treatment of invasive aspergillosis. <i>Infectious Diseases Newsletter (New York, N Y)</i> , 1991, 10, 65-69.	0.4	2
616	In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against <i>Aspergillus</i> species. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1991, 10, 49-49.	2.9	1
617	Pulmonary Aspergillosis in the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1991, 324, 654-662.	27.0	509
618	<i>Neisseria lactamica</i> Meningitis Following Skull Trauma. <i>Clinical Infectious Diseases</i> , 1991, 13, 216-218.	5.8	30
619	Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis.. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 1329-1333.	3.2	81
620	Ulcerative Tracheobronchitis after Lung Transplantation: A New Form of Invasive Aspergillosis. <i>The American Review of Respiratory Disease</i> , 1991, 144, 552-556.	2.9	257
621	Endocarditis Due to <i>Trichosporon beigeli</i> : In Vitro Susceptibility of Isolates and Review. <i>Clinical Infectious Diseases</i> , 1991, 13, 383-386.	5.8	35
622	Adjunctive Therapy of Allergic Bronchopulmonary Aspergillosis with Itraconazole. <i>Chest</i> , 1991, 100, 813-819.	0.8	201
623	Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. <i>Journal of Antimicrobial Chemotherapy</i> , 1991, 28, 1-16.	3.0	122
624	Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. <i>Journal of Clinical Microbiology</i> , 1991, 29, 333-339.	3.9	69
625	Pulmonary infection in the immunocompromised host. <i>Current Opinion in Infectious Diseases</i> , 1990, 3, 207-215.	3.1	0
626	Cyclosporine and Itraconazole Interaction in Heart and Lung Transplant Recipients. <i>Annals of Internal Medicine</i> , 1990, 113, 327.	3.9	130
627	In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against <i>Aspergillus</i> species. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1990, 9, 693-697.	2.9	17
628	Itraconazole Therapy for Chronic Coccidioidal Meningitis. <i>Annals of Internal Medicine</i> , 1990, 112, 108.	3.9	139
629	Treatment of Coccidioidal Meningitis with Fluconazole. <i>Clinical Infectious Diseases</i> , 1990, 12, S380-S389.	5.8	84
630	The relationship between 'normal' fluid retention in women and idiopathic oedema.. <i>Postgraduate Medical Journal</i> , 1990, 66, 363-366.	1.8	11

#	ARTICLE	IF	CITATIONS
631	Transplacental transfer of aflatoxin in humans. <i>Carcinogenesis</i> , 1990, 11, 1033-1035.	2.8	90
632	High Serum Concentrations of Aflatoxin in Nepal as Measured by Enzyme-Linked Immunosorbent Serum Assay. <i>Human and Experimental Toxicology</i> , 1990, 9, 143-146.	2.2	4
633	Adverse events associated with itraconazole in 189 patients on chronic therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1990, 26, 561-566.	3.0	193
634	Restriction Endonuclease Analysis of Total Cellular DNA of <i>Aspergillus fumigatus</i> Isolates of Geographically and Epidemiologically Diverse Origin. <i>Journal of Infectious Diseases</i> , 1990, 162, 1151-1158.	4.0	134
635	Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 593-601.	1.2	83
636	Itraconazole in opportunistic mycoses: Cryptococcosis and aspergillosis. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 602-607.	1.2	60
637	Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases. <i>Clinical Infectious Diseases</i> , 1990, 12, 1147-1201.	5.8	834
638	Oral Itraconazole Therapy of Cryptococcal Meningitis and Cryptococcosis in Patients with AIDS. , 1990, , 305-324.		20
639	Comparison of <i>Guizotia abyssinica</i> seed extract (birdseed) agar with conventional media for selective identification of <i>Cryptococcus neoformans</i> in patients with acquired immunodeficiency syndrome. <i>Journal of Clinical Microbiology</i> , 1990, 28, 2565-2567.	3.9	29
640	Immunoassay of Aflatoxin in Food and Human Tissue. <i>Toxin Reviews</i> , 1989, 8, 69-79.	1.5	6
641	Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis. <i>Archives of Internal Medicine</i> , 1989, 149, 2301.	3.8	173
642	Clinical Features of Peritoneal Tuberculosis. <i>Journal of Infectious Diseases</i> , 1989, 160, 344-345.	4.0	4
643	Treatment of invasive aspergillosis with itraconazole. <i>American Journal of Medicine</i> , 1989, 86, 791-800.	1.5	393
644	TRANSMISSION OF EPSTEIN-BARR VIRUS BY A TRANSPLANTED KIDNEY, WITH ACTIVATION BY OKT3 ANTIBODY. <i>Transplantation</i> , 1989, 48, 141-144.	1.0	18
645	Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study. <i>Journal of Clinical Microbiology</i> , 1989, 27, 1352-1356.	3.9	51
646	Measurement of aflatoxin in Nigerian sera by enzyme-linked immunosorbent assay. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1988, 82, 169-171.	1.8	18
647	Eradication of Low-Level Methicillin-Resistant <i>Staphylococcus aureus</i> Skin Colonization with Topical Mupirocin. <i>Infection Control and Hospital Epidemiology</i> , 1988, 9, 261-263.	1.8	10
648	Myocarditis complicating ethylene glycol poisoning in the absence of neurological features. <i>Postgraduate Medical Journal</i> , 1988, 64, 867-870.	1.8	12

#	ARTICLE	IF	CITATIONS
649	An ELISA method for the rapid and simple determination of aflatoxin in human serum. Food Additives and Contaminants, 1988, 5, 609-619.	2.0	16
650	Analysis of UK Sera for Aflatoxin by Enzyme-linked Immunosorbent Assay. Human Toxicology, 1988, 7, 353-356.	0.9	22
651	Infant with two relapses of Group B streptococcal sepsis documented by DNA restriction enzyme analysis. Pediatric Infectious Disease Journal, 1988, 7, 729-732.	2.0	19
652	Eradication of Low-Level Methicillin-Resistant <i>Staphylococcus aureus</i> Skin Colonization with Topical Mupirocin. Infection Control and Hospital Epidemiology, 1988, 9, 261-263.	1.8	13
653	Idiopathic oedema and diuretics. Postgraduate Medical Journal, 1987, 63, 25-26.	1.8	6
654	Skin rash after triple vaccine.. Archives of Disease in Childhood, 1987, 62, 510-511.	1.9	5
655	Neuralgic amyotrophy due to parvovirus infection.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 641-642.	1.9	31
656	WHOLE BLOOD EXCHANGE AS TREATMENT FOR LEGIONELLOSIS. Lancet, The, 1987, 329, 227.	13.7	3
657	Invasive pulmonary aspergillosis diagnosed by blood culture and successfully treated. British Journal of Diseases of the Chest, 1987, 81, 300-304.	0.5	10
658	Death Due to Carbamazepine Self-poisoning: Remedies Reviewed. Human Toxicology, 1985, 4, 255-260.	0.9	31
659	COLOURING AGENTS IN MEDICINE FOR ASTHMATIC CHILDREN. Lancet, The, 1985, 325, 461-462.	13.7	0
660	ARREST OF A DRUG DEALER IN HOSPITAL. Lancet, The, 1985, 326, 336.	13.7	0
661	FURTHER PROBLEMS WITH THEOPHYLLINE. Lancet, The, 1984, 323, 223.	13.7	2
662	Chronic Aspergillosis. , 0, , 319-331.		3
663	The Global Incidence of Fungal Keratitis. SSRN Electronic Journal, 0, , .	0.4	5
664	Current situation of fungal diseases in Eritrea. Mycoses, 0, , .	4.0	3